[1]
|
Gomes de Morais, A.L., Cerdá, S. and de Miguel, M. (2022) New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors. Current Oncology Reports, 24, 651-658. https://doi.org/10.1007/s11912-022-01218-y
|
[2]
|
吴畏, 等. 前列腺癌内分泌治疗现状及进展[J]. 现代泌尿生殖肿瘤杂志, 2015, 7(5): 316-318.
https://kns.cnki.net/kcms2/article/abstract?v=3uoqIhG8C44YLTlOAiTRKibYlV5Vjs7ijP0rjQD-AVm8oHBO0FTadhZOvv4_Rvy_ty6_dXgjQw3LjLwPjr1oKqIzmTpjIbwR&uniplatform=NZKPT
|
[3]
|
Arnold, R.S., et al. (2015) Bone Metastasis in Prostate Cancer: Recurring Mitochondrial DNA Mutation Reveals Selective Pressure Exerted by the Bone Microenvironment. Bone, 78, 81-86. https://doi.org/10.1016/j.bone.2015.04.046
|
[4]
|
王慕文. 前列腺癌综合治疗新进展[J]. 泌尿外科杂志(电子版), 2022, 14(4): 1-3.
https://doi.org/10.20020/j.CNKI.1674-7410.2022.04.01
|
[5]
|
曾浩, 等. 势抵抗性前列腺癌最新指南解读——暨中国西部专家共识[J]. 现代泌尿外科杂志, 20217, 22(2): 85-94.
https://kns.cnki.net/kcms2/article/abstract?v=3uoqIhG8C44YLTlOAiTRKibYlV5Vjs7iAEhECQAQ9aTiC5B
jCgn0Rlkj6s9JBQcr5c97LdPJHEpoOV7TboyyFTjQO3pOsSy-&uniplatform=NZKPT
|
[6]
|
Jalili-Nik, M., Soltani, A., Mashkani, B., Rafatpanah, H. and Hashemy, S.I. (2021) PD-1 and PD-L1 Inhibitors Foster the Progression of Adult T-Cell Leukemia/Lymphoma. International Immunopharmacology, 98, Article ID: 107870.
https://doi.org/10.1016/j.intimp.2021.107870
|
[7]
|
Singh, V., et al. (2021) Emerging Role of PD-1/PD-L1 Inhibi-tors in Chronic Liver Diseases. Frontiers in Pharmacology, 12, Article 790963. https://doi.org/10.3389/fphar.2021.790963
|
[8]
|
Tumeh, P.C., et al. (2014) PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance. Nature, 515, 568-571. https://doi.org/10.1038/nature13954
|
[9]
|
Ishida, Y., Agata, Y., Shibahara, K. and Honjo, T. (1992) Induced Expression of PD-1, a Novel Member of the Immunoglobulin Gene Superfamily, upon Programmed Cell Death. The EMBO Journal, 11, 3887-3895.
https://doi.org/10.1002/j.1460-2075.1992.tb05481.x
|
[10]
|
Dong, H., Zhu, G., Tamada, K. and Chen, L. (1999) B7-H1, a Third Member of the B7 Family, Co-Stimulates T-Cell Proliferation and Interleukin-10 Secretion. Nature Med-icine, 5, 1365-1369. https://doi.org/10.1038/70932
|
[11]
|
Gauen, L.K., et al. (1994) Interactions of P59fyn and ZAP-70 with T-Cell Receptor Activation Motifs: Defining the Nature of a Signalling Motif. Molecular and Cellular Bi-ology, 14, 3729-3741.
https://doi.org/10.1128/MCB.14.6.3729
|
[12]
|
Chemnitz, J.M., Parry, R.V., Nichols, K.E., June, C.H. and Riley, J.L. (2004) SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. Journal of Immunology, 173, 945-954.
https://doi.org/10.4049/jimmunol.173.2.945
|
[13]
|
Hui, E., et al. (2017) T Cell Costimulatory Receptor CD28 Is a Primary Target for PD-1-Mediated Inhibition. Science, 355, 1428-1433. https://doi.org/10.1126/science.aaf1292
|
[14]
|
Butte, M.J., Keir, M.E., Phamduy, T.B., Sharpe, A.H. and Freeman, G.J. (2007) Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses. Immunity, 27, 111-122.
https://pubmed.ncbi.nlm.nih.gov/17629517/
https://doi.org/10.1016/j.immuni.2007.05.016
|
[15]
|
Freeman, G.J., et al. (2000) Engagement of the PD-1 Im-munoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. Jour-nal of Experimental Medicine, 192, 1027-1034.
https://pubmed.ncbi.nlm.nih.gov/11015443/
https://doi.org/10.1084/jem.192.7.1027
|
[16]
|
Liu, J., et al. (2021) PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Frontiers in Pharmacology, 12, Article 731798. https://doi.org/10.3389/fphar.2021.731798
|
[17]
|
Kantoff, P.W., et al. (2010) Sipuleucel-T Immunotherapy for Cas-tration-Resistant Prostate Cancer. The New England Journal of Medicine, 363, 411-422. https://doi.org/10.1056/NEJMoa1001294
|
[18]
|
Robert, C., et al. (2015) Nivolumab in Previously Untreated Mela-noma without BRAF Mutation. New England Journal of Medicine, 372, 320-330. https://pubmed.ncbi.nlm.nih.gov/25399552/
|
[19]
|
Vitkin, N., Nersesian, S., Siemens, D.R. and Koti, M. (2019) The Tumor Immune Contexture of Prostate Cancer. Frontiers in Immunology, 10, Article 603. https://doi.org/10.3389/fimmu.2019.00603
|
[20]
|
Robinson, D., et al. (2015) Integrative Clinical Genomics of Ad-vanced Prostate Cancer. Cell, 161, 1215-1228.
https://doi.org/10.1016/j.cell.2015.05.001
|
[21]
|
Moussa, M., Papatsoris, A., Sryropoulou, D., et al. (2021) A Pharmacoeconomic Evaluation of Pharmaceutical Treatment Options for Prostate Cancer. Expert Opinion on Pharma-cotherapy, 22, 1685-1728.
https://doi.org/10.1080/14656566.2021.1925647
|
[22]
|
Heo, E.J., Cho, Y.J., Cho, W.C., et al. (2017) Pa-tient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. Cancer Research & Treatment, 49, 915-926. https://doi.org/10.4143/crt.2016.322
|
[23]
|
Xia, L., Liu, Y. and Wang, Y. (2019) PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. The Oncologist, 24, S31-S41.
https://doi.org/10.1634/theoncologist.2019-IO-S1-s05
|
[24]
|
Li, Z.-Q., et al. (2020) Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors versus Platinum-Based Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta Analysis of Randomized Controlled Trials. Pharmacological Research, 160, Article ID: 105194. https://doi.org/10.1016/j.phrs.2020.105194
|
[25]
|
Han, Y., Liu, D. and Li, L. (2020) PD-1/PD-L1 Pathway: Current Researches in Cancer. American Journal of Cancer Research, 10, 727-742.
|
[26]
|
Gubin, M.M. and Schreiber, R.D. (2015) The Odds of Immunotherapy Success. Science, 350, 158-159.
https://doi.org/10.1126/science.aad4140
|
[27]
|
Pfister, D.G., Ang, K.K., Brizel, D.M., et al. (2013) Head and Neck Cancers, Version 2.2013. Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network, JNCCN, 11, 917-923.
|
[28]
|
Aparicio, T. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency: Le DT (2015) N Engl J Med May 30. Côlon & Rectum, 9, 182-184. https://doi.org/10.1007/s11725-015-0588-4
|
[29]
|
Graff, J.N., Alumkal, J.J., Drake, C.G., et al. (2016) First Evi-dence of Significant Clinical Activity of PD-1 Inhibitors in Metastatic, Castration Resistant Prostate Cancer (mCRPC). Annals of Oncology, 27, Article No. VI244.
https://doi.org/10.1093/annonc/mdw372.03
|
[30]
|
Boudadi, K., et al. (2017) Phase 2 Biomarker-Driven Study of Ipilimumab plus Nivolumab (Ipi/Nivo) for ARV7-Positive Metastatic Castrate-Resistant Prostate Cancer (MCRPC). Journal of Clinical Oncology, 35, 5035-5035.
https://doi.org/10.1200/JCO.2017.35.15_suppl.5035
|
[31]
|
Antonarakis, E.S., Lu, C., Wang, H., et al. (2014) AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. New England Journal of Medicine, 371, 1028-1038. https://doi.org/10.1056/NEJMoa1315815
|
[32]
|
Slovin, S.F., Higano, C.S., Hamid, O., et al. (2013) Ipilimumab Alone or in Combination with Radiotherapy in Metastatic Castration-Resistant Prostate Cancer: Results from an Open-Label, Multicenter Phase I/II Study. Annals of Oncology, 24, 1813-1821. https://doi.org/10.1093/annonc/mdt107
|
[33]
|
Fakhrejahani, F., et al. (2017) Avelumab in Metastatic Castra-tion-Resistant Prostate Cancer (mCRPC). Journal of Clinical Oncology, 35, 5037-5037. https://doi.org/10.1200/JCO.2017.35.15_suppl.5037
|
[34]
|
Velho, P.I. and Antonarakis, E.S. (2018) PD-1/PD-L1 Pathway Inhibitors in Advanced Prostate Cancer. Expert Review of Clinical Pharmacology, 11, 475-486. https://doi.org/10.1080/17512433.2018.1464388
|